<DOC>
	<DOCNO>NCT02329860</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , phase III trial . This clinical study evaluate efficacy safety Apatinib patient advance liver cancer progress Systemic Therapy ( Chemotherapy and/or Targeted Therapy ) . Approximately 360 patient meet entry criterion randomly assign 2:1 ratio Apatinib placebo ( 1/3 chance receive placebo ) . Primary endpoint study overall survival .</brief_summary>
	<brief_title>Study Apatinib After Systemic Therapy（Chemotherapy and/or Targeted Therapy） Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . ≥ 18 year old . 2 . Conform clinical diagnosis standard strictly histological cytological confirmation HCC ( hepatocellular carcinoma ) benefit treatment establish efficacy high priority resection , local ablation , least one unidimensional measurable lesion compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) accord RECIST 1.1 . 3 . Failure intolerance prior treatment chemotherapy and/or target therapy ( Failure define documented radiological progression accord radiology charter . Intolerance define ≥ grade 4 hematologic toxicity , ≥ grade 3 nonhematologic toxicity ≥ grade 2 heart , liver kidney damage ) . 4 . Systemic therapy must complete ≥2 week randomization ( AEs due prior treatment ≤ grade 1 ) . 5 . Liver function status ChildPugh Class A B ( score≤7 ) . 6 . Barcelona Clinic Liver Cancer stage Category B C. 7 . Eastern Cooperative Oncology Group Performance Status 0 1 within 1 week randomization . 8 . Life expectancy least 12 week . 9 . HBV DNA ≤ 2000IU/ml 1×10E+4 copy/ml . 10 . Adequate bone marrow , liver renal function assess follow laboratory test conduct within 1 week randomization . HB ≥ 90g/L ; ANC≥1.5×10E+9/L ; PLT≥80×10E+9/L ; ALB ≥ 29g/L ; ALT AST &lt; 5×ULN ; TBIL ≤1.5×ULN ; Cr ≤1.5×ULN 11 . Women childbearing potential men must agree use adequate contraception . 1 . Any local treatment ( include limit : resection , radiotherapy , TAE , TACE , TAI , RFA PEI ) within 4 week randomization . 2 . Known hepatic duct carcinoma , mixed cell carcinoma fibrolamellar hepatocellular carcinoma , know history suffer cancer ( except cure skin basal cell carcinoma carcinoma situ cervix ) . 3 . Patients receive liver transplantation . 4 . Ascites clinical symptom , i.e . require Abdominal paracentesis drainage treatment ChildPugh Score＞2 . 5 . Hypertension unable control within normal level follow treatment antihypertension agent ( systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg ) . 6 . Suffered grade II myocardial ischemia myocardial infarction , uncontrolled arrhythmia ( include QT interval male ≥ 450 m , female≥ 470 m ) . 7 . Grade IIIIV cardiac insufficiency , accord NYHA criterion echocardiography check : LVEF &lt; 50 % . 8 . Factors affect oral administration（such Patients unable swallow oral medication , chronic diarrhea ileus etc . situation evidently affect drug oral medication absorption） . 9 . Previous digestive tract bleed history within 6 month evident gastrointestinal bleeding tendency , , ：Esophageal varix bleed risk , local active ulcerative lesion , fecal occult blood≥（++）；if fecal occult blood（+），gastroscope check require . 10 . The Within 28 day ahead randomization , experience abdomen fistula , gastrointestinal perforation , abdominal abscess 11 . Coagulation abnormality ( INR &gt; 1.5 x ULN , PT &gt; ULN +4 second ) , bleed tendency receive thrombolytic anticoagulant therapy ; 12 . Occurrence central nervous system metastatic know brain metastatic ; 13 . Objective evidence previous current pulmonary fibrosis history , interstitial pneumonia , Pneumoconiosis , radiation pneumonitis , drugrelated pneumonia , Pulmonary function damage seriously etc . 14 . Proteinuria ≥ ( ++ ) 24 hour total urine protein &gt; 1.0 g. 15 . Received powerful inhibitor CYP3A4 within 7 day powerful inducer CYP3A4 within 12 day randomization . 16 . Pregnant breastfeeding woman ; patient fertility way adopt effective contraceptive measure . 17 . Mental disorder history , Psychotropic drug abuse history . 18 . Patients bone metastasis , receive Palliative radiotherapy ( radiotherapy area &gt; 5 % marrow area ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>